Introduction
Seasonal influenza infection is considered as one of the major source of mortality in human community, especially among people at high risk. Nowadays, the influenza vaccine design is mainly based on the egg-S derived inactivated vaccines, particularly split or subunit vaccines. The protective efficacy of these vaccines is mainly attributed to the ability to induce neutralizing antibodies against the surface functional domains of Flu viruses. Consequently, these vaccines are less effective against heterologous strains [2, 4] . In addition to seasonal epidemics, animal influenza viruses can also easily adapt to human host by exchanging of gene fragments in intermediated hosts. With the emergence of new variants of influenza, the protective efficacy of seasonal influenza vaccines is also reduced [5] . Accordingly, attention has largely focused on the development of Whole Inactivated Vaccines (WIVs) [2] . Given the preservation of viral antigenic domains upon radiation, we used gamma rays to inactivate the influenza virus strain A/ PR/8/34 [A/Puerto Rico/8/34 (H1N1)] as a candidate to develop WIV.
Material and Methods
Madin-Darby Canine Kidney epithelial cells (MDCK lines) as an appropriate experimental model for influenza virus were used for virus preparation. In this manner, the influenza virus strain A/PR/8/34 [A/Puerto Rico/8/34 (H1N1)] was propagated in DMEM (Dulbecco's Modified Eagle Medium) plus antibiotic, and 10% of Fetal Bovine Serum (FBS) and incubated for 48 hours at 37°c with 5% CO 2 and 95% humidity. Following CPE creation, the viruses were collected and concentrated using ultrafiltration. Concentrated virus titration was performed using a TCID 50% test and irradiated at different doses [15] . Finally, the optimum dose of virus inactivation was calculated. Antigenic properties of irradiated viruses compared to non-irradiated viruses and complete inactivation of the irradiated samples with optimum dose also evaluated by Hemagglutination assay and safety test, respectively [17] .
Results
According to the results obtained from safety test ( Table  1) and Hemagglutination assay (Table 2) , the dose of 28 KGy was determined as the optimum dose of gamma irradiation for complete inactivation of the human influenza virus with an initial titration of 10 5.75 /mL by preserving the antigenic properties.
Discussion
Inactivation of the influenza virus by chemical treatments such as formalin or β-propiolactone induces the viral protein cross-linking, leading to reduce the ability of inactivated viruses to penetrate the host cell cytosol. Physical treatments such as UV rays also impair the effective uptake of inactivated viruses by antigen-presenting cells through interfere with viral lipid membrane activity. Thereby, the efficacy of inactivated vaccines may be reduced by these structural alterations [2, 11, 22] . In contrast, the virucidal effect of gamma irradiation is mainly related to the viral nucleic acid damage [19] . Alternatively, to prevent unwanted protein damages, gamma irradiation can also be applied for frozen samples. This feature is a major advantage of gamma rays over other traditional sterilization methods [23] . Given these advantages, gamma irradiation can be used to inactivate the human influenza virus.
The results of this study showed that the doses of 28 and 30 kGy of gamma irradiation could deactivate the human influenza A/PR/34/8 virus, without altering the virus' antigenic properties.
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